Skip to content
value.today

Amarantus Bioscience Holdings, Inc.

Formerly Amarantus Bioscience, Inc., Amarantus Biosciences, Inc., Jumpkicks, Inc

Total raised
$6 M
3 rounds on record
Latest round
$3 M
Nov 2014
First round on record
Aug 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Amarantus Bioscience Holdings, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2014$3 MNo. 3$2 to $10 million

Amarantus Bioscience Holdings, Inc.: Raise no. 3, Nov 2014

Investors in this round

1 investor had bought by the notice of Nov 17, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Amarantus Bioscience Holdings, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series E 12% Convertible Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Gerald Commissiong · Executive Officer, Director · President and Chief Executive Officer
  • John Commissiong · Executive Officer, Director · Chief Scientific Officer and Director
  • Marc Faerber · Executive Officer · Controller, Vice President of Financial Operations, Treasurer and Secretary
  • Robert Farrell · Executive Officer · Chief Financial Officer
  • David Lowe · Director
  • Donald Huffman · Director
  • Iain Ross · Director · Director and Chairman of the Audit Committee
  • Robert Harris · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gerald Commissiong, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Nov 17, 2014. Read the notice at the SEC.

equitySEC
Sep 2013$1 MNo. 2Under $2 million

Amarantus Bioscience Holdings, Inc.: Raise no. 2, Sep 2013

Investors in this round

5 investors had bought by the notice of Sep 13, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Amarantus Bioscience Holdings, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
$100
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$59,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Dr. John W Commissiong · Executive Officer, Director
  • Gerald E Commissiong · Executive Officer, Director · Chief Executive Office
  • Marc E Faerber · Executive Officer · Chief Financial Officer
  • Mark E Benedyk · Director
  • Robert E Harris · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • GVC Capital LLC (CRD 38923) · Greenwood Village, ColoradoSold in CA, IN, NY

Signed by Marc Faerber, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 13, 2013. Read the notice at the SEC.

debt, optionsSEC
Aug 2013$1 MNo. 1Under $2 million

Amarantus Bioscience Holdings, Inc.: Raise no. 1, Aug 2013

Investors in this round

1 investor had bought by the notice of Aug 28, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Amarantus Bioscience Holdings, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$100
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Dr. John W Commissiong · Executive Officer
  • Gerald E Commissiong · Executive Officer
  • Marc E Faerber · Executive Officer
  • Mark L Benedyk · Director
  • Robert L Harris · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gerald E. Commissiong, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 28, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Amarantus Bioscience Holdings, Inc. had no revenue when it filed its newest notice of a funding round (Nov 2014).

    SEC Form D (revenue range) · Nov 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2014

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Amarantus Bioscience Holdings, Inc.
InvestorKindAmountRoundRoleSource
Gerald CommissiongPersonnot statednot statedHeld Series C preferred stock (Form 3, 2014)SEC Form 3
John Wesley CommissiongPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2015)SEC Form 3
Marc E. FaerberPersonnot statednot statedHeld Series C preferred stock (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 5 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Amarantus Bioscience Holdings, Inc.
NameRoleNamed in
Gerald CommissiongPresident and Chief Executive OfficerNov 2014
John CommissiongChief Scientific Officer and DirectorNov 2014
Marc FaerberController, Vice President of Financial Operations, Treasurer and SecretaryNov 2014
Robert FarrellChief Financial OfficerNov 2014
Dr. John W CommissiongExecutive officerSep 2013
Gerald E CommissiongChief Executive OfficeSep 2013
Marc E FaerberChief Financial OfficerSep 2013
David LoweDirectorNov 2014
Donald HuffmanDirectorNov 2014
Gerald CommissiongPresident and Chief Executive OfficerNov 2014
Iain RossDirector and Chairman of the Audit CommitteeNov 2014
John CommissiongChief Scientific Officer and DirectorNov 2014
Robert HarrisDirectorNov 2014
Dr. John W CommissiongDirectorSep 2013
Gerald E CommissiongChief Executive OfficeSep 2013
Mark E BenedykDirectorSep 2013
Robert E HarrisDirectorSep 2013
Mark L BenedykDirectorAug 2013
Robert L HarrisDirectorAug 2013